Palo Alto Investors

Palo Alto Investors is an investment advisory company that provides money management services. It also operates as a private investment firm that offers long-term investments for high-net-worth and institutional investors based on original and fundamental research. Palo Alto Investors was founded in 1989 and is based in Palo Alto, California.

Ted Janus

Partner and Director of Research

28 past transactions

Gilgamesh Pharmaceuticals

Series A in 2021
Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company founded in 2019 and based in New York, focused on developing innovative psychotropic drugs aimed at treating mental illnesses. The company specializes in oral arylcyclohexylamine and psychedelic medicines designed to address neuropsychiatric conditions such as depression, anxiety, substance use disorders, and stress-related issues. By leveraging a combination of medicinal chemistry, neuroscience, and drug development expertise, Gilgamesh Pharmaceuticals is committed to creating novel chemical entities that can effectively aid patients suffering from central nervous system disorders, thereby enhancing their recovery process.

NewLeaf Symbiotics

Series B in 2014
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs. The Company is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license products beginning in 2014.

NeXeption

Series A in 2014
NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Alimera Sciences

Post in 2012
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Ceptaris Therapeutics

Series D in 2012
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Ceptaris Therapeutics

Series D in 2011
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Revance Therapeutics

Series D in 2011
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Fisker

Private Equity Round in 2011
Fisker, Inc. is a designer and manufacturer of electric vehicles, focusing on eco-friendly and innovative mobility solutions. Headquartered in Manhattan Beach, California, the company aims to create vehicles that evoke strong emotional responses while promoting sustainability. Fisker gained early recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted at the 2008 North American International Auto Show and began deliveries in 2011. However, production of the Karma was halted in November 2012 due to the bankruptcy of its battery supplier. The design and production assets for the Karma were later acquired by a Chinese conglomerate in 2014. Today, Fisker continues to develop electric vehicles, emphasizing both performance and environmental responsibility.

Revance Therapeutics

Series D in 2009
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Fisker

Series C in 2008
Fisker, Inc. is a designer and manufacturer of electric vehicles, focusing on eco-friendly and innovative mobility solutions. Headquartered in Manhattan Beach, California, the company aims to create vehicles that evoke strong emotional responses while promoting sustainability. Fisker gained early recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted at the 2008 North American International Auto Show and began deliveries in 2011. However, production of the Karma was halted in November 2012 due to the bankruptcy of its battery supplier. The design and production assets for the Karma were later acquired by a Chinese conglomerate in 2014. Today, Fisker continues to develop electric vehicles, emphasizing both performance and environmental responsibility.

Fisker

Series B in 2008
Fisker, Inc. is a designer and manufacturer of electric vehicles, focusing on eco-friendly and innovative mobility solutions. Headquartered in Manhattan Beach, California, the company aims to create vehicles that evoke strong emotional responses while promoting sustainability. Fisker gained early recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted at the 2008 North American International Auto Show and began deliveries in 2011. However, production of the Karma was halted in November 2012 due to the bankruptcy of its battery supplier. The design and production assets for the Karma were later acquired by a Chinese conglomerate in 2014. Today, Fisker continues to develop electric vehicles, emphasizing both performance and environmental responsibility.

Revance Therapeutics

Series C in 2007
Revance Therapeutics, Inc. is a biotechnology company focused on the development, manufacture, and commercialization of neuromodulators for aesthetic and therapeutic uses. The company’s lead product, DaxibotulinumtoxinA for injection (DAXI), is undergoing clinical trials for various conditions, including glabellar lines, cervical dystonia, adult upper limb spasticity, and chronic migraine. In addition, DAXI is being evaluated for cosmetic applications such as forehead lines and lateral canthal lines. Revance is also developing DaxibotulinumtoxinA Topical for both therapeutic and aesthetic purposes, and it is working on a biosimilar to BOTOX in collaboration with Mylan. Founded in 1999 and originally known as Essentia Biosystems, the company is headquartered in Newark, California.

Fisker

Series A in 2007
Fisker, Inc. is a designer and manufacturer of electric vehicles, focusing on eco-friendly and innovative mobility solutions. Headquartered in Manhattan Beach, California, the company aims to create vehicles that evoke strong emotional responses while promoting sustainability. Fisker gained early recognition for the Fisker Karma, one of the first luxury plug-in hybrid electric vehicles, which debuted at the 2008 North American International Auto Show and began deliveries in 2011. However, production of the Karma was halted in November 2012 due to the bankruptcy of its battery supplier. The design and production assets for the Karma were later acquired by a Chinese conglomerate in 2014. Today, Fisker continues to develop electric vehicles, emphasizing both performance and environmental responsibility.

Ceptaris Therapeutics

Series C in 2007
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Gemfire

Venture Round in 2007
Gemfire Corporation combines an entrepreneurial atmosphere with an extensive technology base. Founded in 1995, Gemfire specializes in applying planar semi-conductor-type processing technology to create optical solutions for system integrators, through an innovative new family of high-performance telecom and specialty components. Currently, the company has primary operations in Livingston, Scotland (near Edinburgh), as well as aerospace support operations (and additional telecom manufacturing capabilities) in Fremont, California.

Paracor Medical

Series D in 2007
Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

Amicus Therapeutics

Series D in 2006
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

SkyPilot Networks

Venture Round in 2006
SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, specializing in solutions that facilitate cost-effective network services for service providers, municipalities, and public safety agencies. The company offers a patented multi-hop point-to-multipoint architecture that enhances the performance of high-gain directional antennas to improve reach, reduce interference, and optimize spectral efficiency. This technology enables the rapid deployment of various services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. SkyPilot's product lineup includes the SkyPilot Connector Mini and SkyPilot Connector Pro, which provide economical customer premises equipment for long-range connectivity, along with the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record of scalability and reliability, SkyPilot has successfully delivered units to customers in over 50 countries. The company is headquartered in Santa Clara, California.

Mercator MedSystems

Series A in 2006
Mercator MedSystems, Inc. is a medical technology company based in Emeryville, California, specializing in catheter-guided microfluid injection systems for targeted delivery of therapeutic agents across blood vessels. The company develops products such as the Cricket and Bullfrog micro-infusion catheters, which allow for the direct injection of therapies into deep tissues without systemic exposure. These devices are utilized in various treatments, including addressing blood vessel restenosis, peripheral artery disease, and complications related to stenotic dialysis access failure. Mercator's technology supports the infusion of drugs, genes, and cells, preserving their viability and potency for applications in vascular diseases, oncology, and regenerative medicine. Founded in 1999, Mercator MedSystems aims to advance patient outcomes through innovative therapeutic delivery methods.

FlowMedica

Series D in 2005
FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

Amicus Therapeutics

Series C in 2005
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Deem

Series B in 2005
Deem, Inc. is a technology platform based in San Francisco that specializes in solutions for the business travel industry, offering a range of applications for travel, car service, and expense management. Founded in 1999, Deem provides Commerce-as-a-Service (CaaS) to businesses, enabling them to streamline travel bookings and manage expenses efficiently. Its integrated cloud suite allows corporations to control costs, as employees can easily book flights, hotels, and ground transportation, while keeping spending within policy. Additionally, Deem facilitates merchants in promoting their products and services through various consumer engagement strategies, enhancing customer loyalty and broadening market reach. As of January 2019, Deem operates as a subsidiary of Enterprise Holdings, Inc.

SkyPilot Networks

Series C in 2005
SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, specializing in solutions that facilitate cost-effective network services for service providers, municipalities, and public safety agencies. The company offers a patented multi-hop point-to-multipoint architecture that enhances the performance of high-gain directional antennas to improve reach, reduce interference, and optimize spectral efficiency. This technology enables the rapid deployment of various services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. SkyPilot's product lineup includes the SkyPilot Connector Mini and SkyPilot Connector Pro, which provide economical customer premises equipment for long-range connectivity, along with the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record of scalability and reliability, SkyPilot has successfully delivered units to customers in over 50 countries. The company is headquartered in Santa Clara, California.

Talima Therapeutics

Series A in 2005
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Labcyte

Series B in 2002
Labcyte Inc. is a specialized laboratory instrumentation company based in San Jose, California, established in 2000. It focuses on acoustic droplet ejection (ADE) technology, which enables the precise dispensing of nanoliter-scale droplets for various life sciences applications, including drug discovery, genomics research, cancer research, and diagnostic testing. The company's flagship product, Echo, utilizes a focused beam of acoustic energy to transfer small volumes of liquids with high accuracy and minimal waste, thereby reducing consumable costs. Labcyte also offers a range of automation systems, laboratory workstations, and control software to enhance laboratory efficiency. As a subsidiary of Beckman Coulter, Inc., Labcyte has expanded its presence internationally, with offices in countries such as Canada, the United Kingdom, Australia, and several others across Asia. The company was previously known as Picoliter Inc. until it rebranded in 2003.

SkyPilot Networks

Series B in 2001
SkyPilot Networks is a prominent provider of carrier-class broadband wireless equipment, specializing in solutions that facilitate cost-effective network services for service providers, municipalities, and public safety agencies. The company offers a patented multi-hop point-to-multipoint architecture that enhances the performance of high-gain directional antennas to improve reach, reduce interference, and optimize spectral efficiency. This technology enables the rapid deployment of various services, including last-mile Internet access, voice over IP, Wi-Fi hotspots, and video surveillance. SkyPilot's product lineup includes the SkyPilot Connector Mini and SkyPilot Connector Pro, which provide economical customer premises equipment for long-range connectivity, along with the SkyPilot EMS, an element management system that aids in the deployment and management of wireless mesh networks. With a proven track record of scalability and reliability, SkyPilot has successfully delivered units to customers in over 50 countries. The company is headquartered in Santa Clara, California.

Speedera Networks

Venture Round in 2001
Speedera Networks, Inc. was founded in 1999 and is headquartered in Santa Clara, California. The company specialized in distributed application hosting and content delivery services, catering to both industry and government sectors. Its suite of on-demand services addressed critical issues related to performance, scalability, availability, and security for distributed applications and websites. In 2005, Speedera Networks was acquired by Akamai Technologies, further enhancing its capabilities in delivering robust web solutions.

Labcyte

Series A in 2001
Labcyte Inc. is a specialized laboratory instrumentation company based in San Jose, California, established in 2000. It focuses on acoustic droplet ejection (ADE) technology, which enables the precise dispensing of nanoliter-scale droplets for various life sciences applications, including drug discovery, genomics research, cancer research, and diagnostic testing. The company's flagship product, Echo, utilizes a focused beam of acoustic energy to transfer small volumes of liquids with high accuracy and minimal waste, thereby reducing consumable costs. Labcyte also offers a range of automation systems, laboratory workstations, and control software to enhance laboratory efficiency. As a subsidiary of Beckman Coulter, Inc., Labcyte has expanded its presence internationally, with offices in countries such as Canada, the United Kingdom, Australia, and several others across Asia. The company was previously known as Picoliter Inc. until it rebranded in 2003.